MDT

89.59

-0.42%↓

VEEV

282.47

+2.4%↑

A

120.22

-2.5%↓

WBA

11.48

-0.26%↓

HQY

96.31

+1.97%↑

MDT

89.59

-0.42%↓

VEEV

282.47

+2.4%↑

A

120.22

-2.5%↓

WBA

11.48

-0.26%↓

HQY

96.31

+1.97%↑

MDT

89.59

-0.42%↓

VEEV

282.47

+2.4%↑

A

120.22

-2.5%↓

WBA

11.48

-0.26%↓

HQY

96.31

+1.97%↑

MDT

89.59

-0.42%↓

VEEV

282.47

+2.4%↑

A

120.22

-2.5%↓

WBA

11.48

-0.26%↓

HQY

96.31

+1.97%↑

MDT

89.59

-0.42%↓

VEEV

282.47

+2.4%↑

A

120.22

-2.5%↓

WBA

11.48

-0.26%↓

HQY

96.31

+1.97%↑

Search

Coherus Biosciences Inc

Abierto

SectorSalud

0.92 5.75

Resumen

Variación precio

24h

Actual

Mínimo

0.86

Máximo

0.92

Métricas clave

By Trading Economics

Ingresos

-5.9M

-57M

Ventas

-47M

7.6M

P/B

Media del Sector

1.696

39.564

Margen de beneficio

-744.427

Empleados

221

EBITDA

115K

-44M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+357.95% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-32M

87M

Apertura anterior

-4.83

Cierre anterior

0.92

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

133 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Coherus Biosciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jul 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Principales Movimientos del Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Ganancias

BASF Cuts Outlook on Global Economy Uncertainty

13 jul 2025, 23:54 UTC

Charlas de Mercado

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13 jul 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13 jul 2025, 23:49 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 jul 2025, 23:40 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

13 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Advances Amid Rising Trade Tensions -- Market Talk

13 jul 2025, 23:39 UTC

Charlas de Mercado

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13 jul 2025, 23:16 UTC

Ganancias

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13 jul 2025, 23:13 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

13 jul 2025, 23:13 UTC

Charlas de Mercado

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13 jul 2025, 11:00 UTC

Adquisiciones, fusiones, absorciones

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12 jul 2025, 02:24 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 jul 2025, 21:45 UTC

Charlas de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Charlas de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Charlas de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Charlas de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Charlas de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Charlas de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Ganancias

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Charlas de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Ganancias

BASF Will Publish Half-Year Results on July 30

Comparación entre iguales

Cambio de precio

Coherus Biosciences Inc Esperado

Precio Objetivo

By TipRanks

357.95% repunte

Estimación a 12 meses

Media 4.03 USD  357.95%

Máximo 7 USD

Mínimo 1.05 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Coherus Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

3

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.9209 / 1.05Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

133 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.